ACC 2022: VALOR-HCM Demonstrated Benefits of Mavacamten in Obstructive Hypertrophic Cardiomyopathy
After 16 weeks of treatment, most patients no longer met eligibility criteria for septal reduction therapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.